Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD).

13 Oct 2004

Lithium can protect the brain cells involved in learning and memory from radiation damage

Patients who undergo radiation for treatment of brain tumors may survive their cancer only to have lasting memory and learning deficiencies, the impact of which can be particularly devastating for children.

10 Oct 2004

FDA fast tracks Genaera's drug for the treatment of wet age-related macular degeneration

Genaera Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to squalamine, an intravenously administered, first in class, small molecule anti-angiogenic drug for the treatment of "wet" age-related macular degeneration (AMD).

4 Oct 2004

Novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread

By studying cancer in mice, researchers at The University of Texas at Austin have gained preliminary evidence that a novel compound that resembles vitamin E halves the size of tumors and the ability of cancer to spread to other body sites.

30 Sep 2004

Researchers show gossypol – a drug refined from cottonseed oil is a cancer treatment booster

New research has opened up the prospect that gossypol – a drug refined from cottonseed oil and previously tried and abandoned as a male contraceptive – could boost the effectiveness of treatment for prostate tumours and possibly other common cancers as well.

30 Sep 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Arsenic trioxide - invented as a treatment for a rare type of leukaemia

Arsenic trioxide – a highly poisonous substance best known as an effective weed killer or pesticide and notorious for being a favourite ‘weapon’ of choice in murder mystery novels, is being re-invented as a treatment for a rare type of leukaemia.

28 Sep 2004

Four or more glasses of red wine per week may reduce risk of prostate cancer by 50 percent

Drinking a glass of red wine a day may cut a man's risk of prostate cancer in half, and the protective effect appears to be strongest against the most aggressive forms of the disease

23 Sep 2004

New link in the growth of Ewing’s sarcoma

To develop new therapeutic approaches to cancer, it is essential to understand the long and extremely complex process that underlies it, in other words the various stages of cancer development from the initial mutation to the tumor.

23 Sep 2004

Scientists have corrected a flaw in cancer cells that lets them evade the normal cell-death process

Scientists at Dana-Farber Cancer Institute have corrected a flaw in cancer cells that lets them evade the normal cell-death process, and as a result they eliminated leukemia cells from mice.

21 Sep 2004

New anti-inflammatory strategy for cancer therapy

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system’s inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

20 Sep 2004

Potential stem cells treatment for retinitis pigmentosa and other retinal degenerations

A team of researchers from The Scripps Research Institute was able to preserve visual function in mice that were genetically predisposed to developing a profound degenerative disease that destroys their retinas.

16 Sep 2004

Protein that causes juvenile Batten disease also plays a key role in normal cell function

The aberrant protein that causes juvenile Batten disease, a fatal neurodegenerative disorder of childhood, also plays a key role in normal cell function, Duke University Medical Center researchers have found.

16 Sep 2004

Cancers, including colon, prostate, and leukemia, continue to grow unchecked

Many cancers, including colon, prostate, and leukemia, continue to grow unchecked because they do not respond to a signal to die and stop proliferating from Transforming Growth Factor-beta (TGF-b).

8 Sep 2004

Researchers uncover how HIV causes abnormalities in antibody-producing cells

HIV wreaks much of its damage by targeting the “orchestra conductor” of the immune system, a key class of T cells—CD4+ T cells—whose destructive relationship with HIV has been well-studied by AIDS researchers.

8 Sep 2004

New ways of looking at treatment for lung diseases such as pulmonary fibrosis

A research team at Yale University has found that blocking a kind of cell death called apoptosis in fibrotic diseases of the lung, also blocks the fibrosis, opening new ways of looking at treatment for lung diseases such as pulmonary fibrosis.

2 Sep 2004

Chemotherapy experts refute ASCO recommendations on use of drug sensitivity and resistance assays

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

1 Sep 2004

Researchers discover that DNA fragments destroy melanoma cells

Researchers at Boston University School of Medicine have discovered that small DNA fragments or oligonucleotides that resemble the telomere (chromosome end), also called T-oligos, can cause human melanoma cells to undergo extensive apoptosis (cell death), while surviving melanoma cells become more differentiated and therefore less aggressive.

1 Sep 2004

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.

25 Aug 2004

Dual-action compound shows promise in killing prostate cancer cells

Ohio State University researchers are working on developing a multi-purpose cancer drug that might one day scale back the number of medications some cancer patients need to take.

22 Aug 2004